Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofogliflozin vs metformin for liver fat in NAFLD with type 2 diabetes
jRCTs031190040Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tofogliflozin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Primary: Change in liver fat content at 24 weeks (between arms). Started Oct 2019; status: completed.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCTs031190040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190040.